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SUMMARY
Background
Advances in hepatitis C therapies have led to increasing numbers of patients
seeking treatment. As a result, logistical and ﬁnancial concerns regarding how
treatment can be provided to all patients with chronic hepatitis C (CHC) have
emerged.
Aim
To evaluate predictors and predictive models of histological progression and
clinical outcomes for patients with CHC.
Methods
MEDLINE via PubMed, EMBASE, Web of Science and Scopus were searched
for studies published between January 2003 and June 2014. Two authors inde-
pendently reviewed articles to select eligible studies and performed data abstrac-
tion.
Results
Twenty-nine studies representing 5817 patients from 20 unique cohorts were
included. The outcome incidence rates were widely variable: 16–61% during
median follow-up of 2.5–10 years for ﬁbrosis progression; 13–40% over 2.3–
14.4 years for hepatic decompensation and 8–47% over 3.9–14.4 years for overall
mortality. Multivariate analyses showed that baseline steatosis and baseline ﬁbro-
sis score were the most consistent predictors of ﬁbrosis progression (signiﬁcant
in 6/21 and 5/21, studies, respectively) while baseline platelet count (signiﬁcant
in 6/13 studies), aspartate and alanine aminotransferase (AST/ALT) ratio, albu-
min, bilirubin and age (each signiﬁcant in 4/13 studies) were the most consistent
predictors of clinical outcomes. Five studies developed predictive models but
none were externally validated.
Conclusions
Our review identiﬁed the variables that most consistently predict outcomes of
patients with chronic hepatitis C allowing the application of risk based
approaches to identify patients in need of early treatment and intensive moni-
toring. This approach maximises effective use of resources and costly new
direct-acting anti-viral agents.
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INTRODUCTION
With the introduction of more efﬁcacious and less toxic
drugs, treatment of chronic hepatitis C (CHC) is evolv-
ing at a rapid pace. The two new direct-acting anti-viral
agents (DAA), simeprevir and sofosbuvir, increase rates
of sustained virological response (SVR) with shorter
treatment durations compared to prior therapies.1, 2
Along with advances in therapy, there has been a focus
on the public health impact of CHC. The Centers for
Disease Control and Prevention, the Institute of Medi-
cine, and the United States Preventive Services Task
Force, have prioritised hepatitis C awareness, screening
and diagnosis.3–5 Treatment is also being advocated as a
means to prevent hepatitis C virus (HCV) infection. As
a result of these processes, the pool of potential treat-
ment candidates is expected to balloon. This has caused
the conundrum in HCV treatment to shift from ‘Can we
improve the efﬁcacy and tolerability of HCV treatment?’
to ‘Can we afford to treat all patients with CHC?’
At the core of the dilemma is the high cost of these
new drugs. The estimated wholesale price of a 12-week
course of sofosbuvir in the United States (US) is $84 000
and of simeprevir $66 000.6, 7 These staggering costs
exclude retail markup, and associated cost of pegylated
interferon (IFN), ribavirin, physician visits and labora-
tory tests. While these new treatment regimens have
SVR rates of 80–90%, and SVR has been shown to
decrease cirrhosis complications, hepatocellular carci-
noma (HCC) and liver-related mortality, even resour-
ce-replete countries like the US cannot afford to treat all
those who are infected.1, 2, 8 The logistical and ﬁnancial
barriers are much higher in resource-limited countries,
many of which have higher prevalence of HCV infection
than western countries. Clinicians and health policy
makers will need to determine an optimal yet practical
approach to provide these highly efﬁcacious, but extre-
mely costly therapies to this burgeoning patient popula-
tion.
One solution is to adopt a risk-stratiﬁed approach that
targets therapy to those at the greatest risk of disease
progression. There have been many studies investigating
risk factors for disease progression in patients with CHC
but few have employed a longitudinal study design in
generalisable patient populations using data that are rou-
tinely available in clinical practice. Results of the existing
studies have also not been systematically summarised in
a single document. Therefore, we performed a systematic
review of the literature to (i) identify factors predictive
of disease progression (ﬁbrosis progression and clinical
outcomes) in patients with CHC and (ii) assess existing
predictive models.
METHODS
Data sources and search strategy
We followed the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) recommen-
dations in conducting this systematic review.9 With the
assistance of a medical research librarian, we performed
serial literature searches for English and non-English
articles. MEDLINE (via PubMed), EMBASE, Web of Sci-
ence and Scopus were searched using the following key-
words: ‘cirrhosis’ or ‘liver cirrhosis’ or ‘ﬁbrosis’, ‘hepatitis
C’ or ‘hepatitis C, chronic’ or ‘chronic hepatitis C’, ‘dis-
ease progression’ or ‘progression’ or ‘decompensation’.
Boolean operators and medical subject heading terms as
well as other controlled vocabulary were used to enhance
electronic searches. An example of speciﬁc search strat-
egy details is shown in Table S1.
All human subject studies published in full-text or
abstract were eligible for inclusion. The search was lim-
ited to publications from 2003 to 2014 as this 10-year
period contained the most contemporary and relevant
data with respect to treatment and current practice.
Additional studies of interest were identiﬁed by hand
searches of bibliographies and cited reference tracking
and consultation with clinical experts on the topic. The
initial search was performed in October 2013 and the
search was last updated on 2 June 2014.
Study eligibility and selection criteria
Two authors (M.A.K. and A.S.L.) sequentially deter-
mined study eligibility. Studies were initially screened by
the ﬁrst author; decisions about study inclusion were
made independently by both authors (M.A.K and A.S.L).
Differences in opinion regarding study inclusion were
resolved through consensus. Studies were included if
they: (i) included human studies with participants
18 years of age or older; (ii) systematically evaluated pre-
dictors of ﬁbrosis progression and/or clinical outcomes
for patients with CHC; and (iii) used a longitudinal
cohort study design. We focused on studies of untreated
patients but also included studies with a mix of treated
and untreated patients provided that <20% of the study
population achieved SVR and results were stratiﬁed by
treatment outcomes. For studies evaluating predictors of
ﬁbrosis progression, we selected studies only when paired
biopsy was used to assess progression.
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We excluded studies that enrolled (i) patients co-in-
fected with hepatitis B (HBV) or human immunodeﬁ-
ciency virus (HIV); (ii) patients with additional causes of
chronic liver disease; (iii) patients with prior liver trans-
plantation and (iv) speciﬁc groups of patients (e.g. thal-
assaemia patients) only. These patient populations were
excluded because they likely have different rates and risk
factors for disease progression compared to the general
population of patients with CHC. In addition, studies
that evaluated HCC as the only outcome of interest were
excluded as we were interested in broad clinical out-
comes for patients with CHC, and predictors of HCC
development alone may not be the same as predictors of
disease progression in CHC in general. Lastly, studies
that focused on predictors that are not readily available
clinically (e.g. genetic or other serum markers for which
commercial assays are not available, and experimental
imaging techniques) were excluded given that they would
not be relevant to current clinical practice.
Deﬁnition of variables and outcomes
Patients with CHC were deﬁned as those with detectable
HCV ribonucleic acid (RNA). We were interested in two
outcomes: histological progression and clinical progres-
sion. The deﬁnition of histological progression was an
increase of ≥1 METAVIR (range 0–4) or Ishak (range 0–
6) ﬁbrosis stage on follow-up liver biopsy. The deﬁnition
of clinical progression encompassed the progression from
compensated to decompensated cirrhosis, and liver-re-
lated or overall mortality. The deﬁnition of compensated
cirrhosis was based on histology when available (Ishak
ﬁbrosis score ≥5 or METAVIR 4) or on the combined
results of other noninvasive testing including laboratory
tests and imaging. Decompensated cirrhosis was deﬁned
by the presence of any of the following: ascites, sponta-
neous bacterial peritonitis (SBP), variceal bleeding or
hepatic encephalopathy (HE). The presence of HCC as
deﬁned by histology or American Association for Study
of Liver Diseases radiological criteria was variably
included as a clinical outcome.10
Data abstraction and validity assessment
Data from eligible studies were abstracted by two authors
(M.A.K. and S.Y.) using a standardised template adapted
from the Cochrane Collaboration.11 For all studies, we
recorded: study design, sample size, patient population
characteristics, duration of follow-up, predictor variables
studied, outcomes measured, criteria used to deﬁne these
outcomes and measures of association/predictiveness of
risk for these outcomes. We accepted the outcome deﬁ-
nitions as stated by each study without independently
validating or reviewing their data. Study authors were
directly contacted for additional, unpublished data.
Assessment of risk of bias and study quality
Two authors (M.A.K and S.Y.) independently assessed the
risk of study bias and study quality. Since all the included
studies were nonrandomised cohort studies, the Newcas-
tle-Ottawa scale was used to judge study quality as recom-
mended by the Cochrane Collaboration.12 This scale uses
a star system to assess the quality of a study based on three
domains: selection of the study population, comparability
of the study groups and method of outcomes assessment.
For our review, given that no study had a comparison
group, we excluded comparability components of the scale
across all studies. Studies which received stars in every
domain were assessed as being of high quality.
Data synthesis and analysis
Given the substantial variation in the design, methods and
inclusion/exclusion criteria within our included studies,
meta-analysis was not performed. Two authors (M.A.K.
and S.Y.) qualitatively synthesised the results of the
included studies, focusing on the risk factors evaluated
and their independent predictiveness in terms of the out-
comes measured and patient populations studied. Studies
were categorised according to the outcome of interest:
predictors of histological progression, predictors of clini-
cal outcomes or studies investigating both clinical and his-
tological outcomes. All authors had access to the study
data and had reviewed and approved the ﬁnal manuscript.
RESULTS
Studies included in the systematic review
After removal of duplicate entries, 2257 unique articles
were identiﬁed by our systematic literature search
(Figure 1). On the basis of abstract review, 69 were
selected for full-text review. Two study authors classiﬁed
29 articles as meeting the predeﬁned criteria for analysis.
In total, these 29 studies included 5817 unique patients
from 20 separate patient cohorts. Sixteen of these studies
investigated predictors of histological progression, eight
studies evaluated predictors of clinical outcomes, and the
remaining ﬁve studies investigated both histological and
clinical outcomes.13–41 Fourteen studies included treat-
ment-na€ıve patients only, ﬁve included both treat-
ment-na€ıve and treatment-experienced patients, eight
included treatment-experienced patients only, and two
studies did not describe the treatment status of the
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patients. We contacted four authors to obtain additional
unpublished data.
Characteristics of studies on histological progression
A total of 21 studies evaluated predictors of histological
progression. The studies included populations from
Europe (n = 10), Asia (n = 2), and North (n = 8) and
South America (n = 1). Only one study was prospective
with the remaining 20 being retrospective analyses of
previously collected data. The sample size for included
studies varied (range 36–622 patients) with the majority
having <200 patients (n = 14). A number of studies
Figure 1 | Flow diagram of studies included in the systematic review. aMany studies met multiple exclusion criteria.
Each study was coded under a single criterion only. bIncludes animal models, paediatric populations, patients who had
previously undergone liver transplant, patients with chronic liver disease other than HCV monoinfection, evaluation of
only speciﬁc subsets of populations with CHC. cIncludes studies that were descriptive papers only, studies that did
not speciﬁcally evaluate for predictors of histological or clinical progression, and studies that evaluated predictors that
are not readily clinically available. dIncludes studies that focused on risk factors for the development of HCC only, and
studies where some patients achieved SVR and the results were not stratiﬁed based on response to treatment.
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had overlapping cohorts. Four studies were derived
from the Hepatitis C Anti-viral Long-term Treatment
Against Cirrhosis (HALT-C) cohort, a US multi-centre
randomised controlled trial to evaluate the safety and
efﬁcacy of low dose pegylated IFN in CHC patients
with advanced ﬁbrosis who failed to respond to prior
IFN therapy. Four other pairs of studies drew from the
same cohort of patients.17, 21, 25, 29, 33, 35, 38, 41 These
studies were included in the review despite overlapping
cohorts given differences in predictors examined, out-
comes evaluated and criteria for selection of subsets of
patients analysed within the overall larger cohort. The
average duration of follow-up ranged from a median of
2.5–10 years.
The studies had varied inclusion and exclusion criteria
as detailed in Table 1. Among the non-HALT-C studies,
11 studies had explicit requirements for baseline Ishak/
METAVIR ﬁbrosis stage. Five studies required minimal
or no ﬁbrosis at baseline and the remaining six studies
required lack of cirrhosis on initial biopsy. Only 14 stud-
ies described criteria used to determine adequacy of
biopsy specimens. The majority of the studies had a sin-
gle pathologist blinded to clinical data score the biopsies
while the HALT-C study had a panel of pathologists
review the biopsies and consensus staging was recorded.
Exclusionary alcohol intake was described in nine studies
though the cut-off amounts and methods for ascertaining
alcohol intake varied across the studies. The studies were
predominately comprised of male patients in their late
30s to early 50s.
Characteristics of studies of clinical outcomes
A total of 13 studies evaluated predictors of clinical
outcomes. Six studies were conducted in the US
(including 5 HALT-C studies), ﬁve in Europe and two
in Asia. Only two studies were prospective with the
remaining 11 being retrospective analyses. Sample size
in each study varied from 52 to 1457 patients. Apart
from the HALT-C studies, there was only one addi-
tional overlapping cohort.36, 37 The average duration of
follow-up ranged from a median of 2.3 to a maximum
of 14.4 years. Compared to studies on histological pro-
gression, the studies on clinical outcomes consisted of
patients who were older, had more advanced ﬁbrosis
at baseline, and were more likely to be treatment
experienced.
Incidence of histological progression
A summary of the speciﬁc outcomes evaluated and inci-
dence of these outcomes in each study is displayed in
Tables 2–4. For studies where the outcome was deﬁned
as ≥1 ﬁbrosis stage increase on follow-up biopsy
(n = 13), the incidence of that outcome ranged from 21–
61% over a range of follow-up of 2.5–
10 years.14, 16, 18, 21, 25, 28–33, 35, 41 Studies applying a
stricter deﬁnition of ﬁbrosis progression (≥2 stage
increase on follow-up biopsy, n = 3) had less variability
in range of incidence of outcome, reporting 22–34% over
a range of follow-up of 3.5–5.8 years.13, 23, 26 Studies
with higher rates of ﬁbrosis progression tended to have
longer follow-up durations (>6 years), though there were
several studies with follow-up of ≥6 years that had low
rates of ﬁbrosis progression. No identiﬁable differences
in patient characteristics between studies with high vs.
low incidence of ﬁbrosis progression were noted.
Incidence of clinical progression
Studies assessing risk factors for clinical progression
(n = 13) included several distinct outcomes. Four studies
evaluating progression from compensated to decompen-
sated cirrhosis reported an incidence between 13%
and 40% over a range of follow-up of 2.3–
14.4 years.15, 24, 31, 34 No clear pattern was identiﬁed
between length of follow-up or patient characteristics and
rate of outcomes. Notably, the deﬁnition of decompensa-
tion varied across studies. Four studies evaluating the inci-
dence of overall mortality reported incidences between 8%
and 47%. The range of follow-up for these studies was
3.9–14.4 years, with a higher rate of outcomes reported in
studies with longer duration of follow-up.15, 27, 39, 40 The
remaining studies used an aggregate outcome encompass-
ing a broad range of clinical end points including decom-
pensation, increase in Child–Turcotte–Pugh score,
development of HCC, liver transplant and liver related as
well as overall mortality. The reported incidence of this
aggregate outcome was 13–31% over a range of follow-up
of 3.5–6.3 years.19, 20, 23, 26, 36, 37
Predictors of histological progression
A detailed list of the predictors evaluated and the
results of univariate analysis is provided in Tables S3–
S5. For each study, the predictor variables were categor-
ised as follows: (i) baseline clinical characteristics
including demographics and relevant co-morbidities; (ii)
baseline laboratory results; (iii) baseline histological fea-
tures or (iv) longitudinal laboratory and histology
results.
All studies investigating predictors of histological pro-
gression evaluated baseline clinical characteristics, base-
line laboratory results and baseline histology results
Aliment Pharmacol Ther 2014; 40: 863-879 867
ª 2014 John Wiley & Sons Ltd
Systematic review: predictors of hepatitis C progression
Table 1 | General characteristics of included studies*
Study and
Country
Sample
size (n)
%
Genotype
1 Age
%
Male
Study population
Inclusion criteria/patient
characteristics Exclusion criteria
Predictors of histological progression
Baran, 2014
Turkey
125 95 Mean
45
38 Ishak <4 on initial biopsy
>9 portal tracts on liver
biopsy
Treatment na€ıve or
non-SVR with prior
treatment
HIV co-infected
Other chronic liver
disease
HCC
History of
immunosuppressive
therapy
Boccato, 2006
Italy
106 62 Mean
41.6
56 METAVIR F0 or F1 on
initial biopsy
Biopsy length >15 mm
and ≥7 portal tracts
Minimum 4 year
follow-up
Treatment na€ıve
Castera, 2003
France
96 62 Mean
41
61 No cirrhosis on initial
biopsy
Treatment na€ıve
HBV or HIV co-infected
Colletta, 2005
Italy
40 30 Median
43.5
55 Ishak ≤2 on initial biopsy
Serial ALT values < 1.2
times ULN
Treatment na€ıve
Cross, 2009
United Kingdom
112 58 Median
44
66 Biopsy length >10 mm
Treatment na€ıve
HBV or HIV co-infected
Other chronic liver
disease
Prior liver transplant
ETOH intake ≥80
g/day (male), ≥60
g/day (female)
Fabris, 2012
Italy
93 52 Median
38
46 Ishak ≤1 on initial biopsy
Persistently normal or near
normal ALT
Treatment na€ıve
Fartoux, 2005
France
135 60 Mean
38.5
59 METAVIR ≤1 on initial
biopsy
Biopsy length >10 mm
Only one known risk
factor for HCV
infection
Treatment na€ıve
HBV or HIV co-infected
Other chronic liver
disease
Prothrombin time >80%
Platelets >150 000/mL
Hyaluronic acid
<85 lg/L
Ghany, 2003
United States
123 70 Mean
41
63 Treatment na€ıve
Khouri, 2003
Brazil
55 NR Mean
38
58 Biopsy length >15 mm
Minimum of 1 year
interval between
biopsies
18–75 years old
Treatment na€ıve
HBV or HIV co-infected
Immunosuppressed
patients
Chronic renal failure
Using ‘potentially
hepatotoxic drugs’
Kurosaki, 2008
Japan
97 88 Median
52
51 No cirrhosis on initial
biopsy
Treatment with IFN
between biopsies
without SVR
HBV or HIV co-infected
Other chronic liver
disease
ETOH consumption
>20 g/d
868 Aliment Pharmacol Ther 2014; 40: 863-879
ª 2014 John Wiley & Sons Ltd
M. A. Konerman et al.
Table 1 | (Continued)
Study and
Country
Sample
size (n)
%
Genotype
1 Age
%
Male
Study population
Inclusion criteria/patient
characteristics Exclusion criteria
Levine, 2006
Ireland
167 100 Mean
53
0 Women infected from
contaminated
immunoglobulin
Biopsy length >15 mm
and ≥5 portal tracts
Treatment na€ıve
Mummadi, 2010
United States
36 NR Median
47
75 No cirrhosis on initial
biopsy
Minimum of 1 year
interval between
biopsies
HBV or HIV co-infected
Other chronic liver
disease
Prior organ transplant
ETOH intake >30 g/day
HCC
Perumalswami, 2006
United States
136 76 Mean
44
58 >10 portal tracts on liver
biopsy
Treatment na€ıve
Decompensated cirrhosis
HBV or HIV co-infected
Other chronic liver
disease
ETOH ≥60 g/day (male),
≥40 g/day (female)
Malignancy
Steroid therapy
Ryder, 2004
United Kingdom
214 34 Median
36
59 No cirrhosis on initial
biopsy
>5 portal tracts
on liver biopsy
Treatment na€ıve
HIV co-infected
Coagulation disorder
Haemodialysis
Tamaki, 2013
Japan
314 NR Mean
53.7
47 Minimum of 1.5 year
interval between
biopsies
Biopsy length >15 mm
IFN between biopsies,
without SVR
HBV or HIV co-infected
ETOH ≥40 g/day
HCC
NASH
Williams, 2011
United Kingdom
282 44 Mean
37
61 Ishak 0 or 1 on initial
biopsy
>5 portal tracts on liver
biopsy
Minimum of 2 year
interval between
biopsies
No treatment during
study
HIV co-infected
Coagulation disorder
Haemodialysis
Predictors of clinical outcomes
Bruno, 2009
Italy
324 63 Median
59
51.1 Compensated cirrhosis
(Child A)
≤70 years old
IFN based treatment
(55%) without SVR
HBV or HIV co-infected
Other chronic liver
disease
HCC
‘unable to attend regular
follow-up visits’
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Table 1 | (Continued)
Study and
Country
Sample
size (n)
%
Genotype
1 Age
%
Male
Study population
Inclusion criteria/patient
characteristics Exclusion criteria
Ghany, 2011
United States
470 94 Mean
49.8
71.3 HALT-C cohort:
Ishak ≥3 on initial
biopsy
Prior treatment with
IFN based therapy
without SVR
Evaluated control
patients without
further treatment
HIV co-infected
Other chronic liver
disease
ETOH abuse within
past year
CTP score ≥7
History of hepatic
decompensation
Platelets <75 000
Neutrophil count
<1500
Haematocrit <33%
HCC or AFP>300 ng/mL
Bilirubin >2.5 mg/dL
Creatinine >1.5 mg/dL
‘Serious medical
disorder’
Use of illicit drugs
within past 2 years
Giannini, 2003
Italy
63 NR Mean
52
73 HBV or HIV co-infected
Other chronic liver
disease
ETOH >40 g/day
Rincon, 2013
Spain
145 NR Median
51
77 Compensated cirrhosis
Treatment na€ıve or non-SVR
Other chronic liver
disease
Prior liver transplant
HCC >3 cm or
multilobular or vascular
invasion
Sinn, 2008
South Korea
647 71 Mean
58.2
49 Compensated cirrhosis
Minimum of 1 year
follow-up
Treatment na€ıve
HBV or HIV co-infected
CTP score >5
HCC
Sinn, 2013
South Korea
232 62 Mean
57.2
38 Compensated cirrhosis
Minimum of 1 year
follow-up
ALT< 40 IU/l at
baseline
Treatment na€ıve
HBV or HIV co-infected
CTP score >5
HCC
VanDerMeer, 2012
Europe and Canada
405 76 Median
48
68 Ishak ≥4 at baseline
Prior treatment with
IFN based therapy
without SVR
HBV or HIV co-infected
Vergniol, 2011
France
1457 58 Mean
51.2
53.4 52% patients with prior
treatment; 38%
without SVR
14% SVR with results
adjusted for treatment
response
HBV co-infected
Other chronic liver
disease
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except for Tamaki et al. who did not evaluate baseline
histological features.38 Only half of the studies evaluated
longitudinal variables which were predominantly serial
aminotransferase levels. Longitudinal biopsy results such
as changes in steatosis score or histological activity index
(HAI) were assessed in only ﬁve studies.16, 22, 28–30 The
predictors that were most consistently evaluated are
listed in Figure 2a. The most common clinical character-
istics assessed were age, gender, HCV genotype, alcohol
intake, body mass index (BMI) and biopsy interval, and
the most common laboratory values evaluated were
platelet count and ALT levels. Baseline histological fea-
tures were also frequently investigated predictors and
were included in >70% of studies.
Multivariable analysis was performed in all but two
studies.19, 31 Variables found to be independently predic-
tive of histological progression are listed in Tables 2 and
4. Among all the variables assessed, baseline steatosis
was most consistently reported as independently predic-
tive of subsequent ﬁbrosis progression (signiﬁcant on
multivariate analysis in 6 of 21 studies) with an odds
ratio (OR) [(95% conﬁdence interval (CI)] of 4.8 (1.3–
18.3) to 14.3 (2.1–111.1).12, 16, 18, 20, 24, 27 Notably, one
study found that effect of baseline steatosis on ﬁbrosis
progression was dependent on baseline ﬁbrosis stage.20
Baseline Ishak/METAVIR ﬁbrosis stage was the next
most consistently identiﬁed independent predictor of his-
tological progression (signiﬁcant on multivariable analy-
ses in ﬁve of 21 studies).20, 25, 30, 33, 35 Only one of these
studies reported the effect size, with adjusted relative risk
of 1.93 (95% CI 1.3–9.0).35 Figure 2a depicts the number
of studies in which individual variables were signiﬁcantly
or not signiﬁcantly predictive of histological progression
on multivariate analyses.
Table 1 | (Continued)
Study and
Country
Sample
size (n)
%
Genotype
1 Age
%
Male
Study population
Inclusion criteria/patient
characteristics Exclusion criteria
Predictors of histological progression and clinical outcomes
Dienstag, 2011
United States
1050
clinical
622
histological
94 Mean
51
71 HALT-C cohort (See
Ghany 2011 above)
517 patients in IFN arm
and 533 control arm
HALT-C cohort (See
Ghany 2011 above)
Everhart, 2009
United States
985
clinical
557
histological
94 Mean
50.2
71 HALT-C cohort (See
Ghany 2011 above)
488 patients from IFN
arm and 497 control
arm
HALT-C cohort (See
Ghany 2011 above)
Fontana, 2010
United States
462
clinical
209
histological
94 Mean
49.5
70.3 HALT-C cohort (See
Ghany 2011 above)
49.4% patients in
IFN arm
HALT-C cohort (See
Ghany 2011 above)
Ghany, 2010
United States
1050
clinical
547
histological
94 Mean
50
71 HALT-C cohort (See
Ghany 2011 above)
517 in IFN arm and
533 in control arm
HALT-C cohort (See
Ghany 2011 above)
Livingston, 2010
United States
52 67 Median
41
51 Alaska Native and
American Indian
persons
Ishak ≤4 on initial biopsy
Treatment na€ıve
HBV or HIV co-infected
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; CTP, Child–Turcotte–Pugh; ETOH, alcohol; HALT-C, hepatitis c anti-viral
long-term treatment against cirrhosis; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HIV, human
immunodeﬁciency virus; IFN, interferon; NASH, nonalcoholic steatohepatitis; SVR, sustained virological response; ULN, upper limit
of normal.
* For select studies, reported data here reﬂect only a subset of the total study population based on the patient population and
outcome of interest for this systematic review.
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Predictors of clinical outcomes
All 13 studies examining predictors of clinical outcomes
included baseline clinical characteristics and laboratory
results (Tables S4 and S5). Baseline histology was
assessed in only eight studies though biopsies were per-
formed in every study. Only three studies incorporated lon-
gitudinal data which consisted of serial laboratory values
only.23, 24, 36 The predictors that were most consistently
Table 2 | Outcomes and predictors evaluated and summary of results: histological progression
Study
Outcomes
evaluated
%
with
outcome
Years follow-up
(s.d.; range)
Predictors signiﬁcant on
multivariate analysis OR (95% CI)
Only patients with minimal ﬁbrosis at baseline
Boccato, 2006 ≥1 METAVIR
stage increase
60 Mean 7.8 (1.51; 5–10) ETOH intake (>40 g/day)
Baseline steatosis
NR
Colletta, 2005 METAVIR ≥2
on follow-up
biopsy
35 Median 6.5 (NR; 2.25–5.5) HCV RNA >8.0 9 106
copies/mL
ETOH intake >20 g/day
NR
Fabris, 2012 ≥1 Ishak stage
increase
61 Median 10 (NR; 5.1–10) HCV RNA >400 000 IU/mL
ETOH intake >30 g/day
IL28B T/* 9 chol ≤175 mg/dL
Follow-up >8 year
4.3 (1.4–13)
100 (8–1300)
4.1 (1.5–11)
4.9 (1.8–13)
Fartoux, 2005 METAVIR 3 or
4 on
follow-up
biopsy
16 Mean 5.2 (2.3; 1.5–13.1) Baseline steatosis 4.8 (1.3–18.3)
Williams, 2011 ≥1 Ishak stage
increase
42 Median 4.4 (NR; 2–16) Age (older)
Median ALT per 10 IU/L
1.34 (1.03–1.74)
1.07 (1.01–1.13)
Includes patients with more advanced ﬁbrosis at baseline
Baran, 2014 ≥2 Ishak stage
increase
22 Mean 5.8 (NR; 1.25–18) Baseline GGT
Follow-up ALT (<40 IU/L)
Treatment experience (failed)
1.03 (1.01–1.5)
0.16 (0.03–0.93)
5.97 (1.81–19.7)
Castera, 2003 ≥1 METAVIR
stage increase
31 Mean 4 (2.6; 0.8–14.6) Worsening steatosis 4.7 (1.3-10.8)
Cross, 2009 ≥1 Ishak stage
increase
21 Median 4.2 (NR; 2.8–6.1) Baseline steatosis 14.3 (2.1-111.1)
Ghany, 2003 ≥1 Ishak stage
increase
39 Mean 3.7 (NR; 0.25–17.6) Baseline Ishak (low)
Baseline HAI
Baseline ALT (elevated)
NR
Khouri, 2003 ≥1 Ludwig
stage increase
27 Mean 3.25 (1.1;1-6.8) None NR
Kurosaki, 2008 ≥1 METAVIR
stage increase
23 Mean 5.9 (NR; 1.2–11.6) Baseline steatosis
Average ALT ≥100 IU/l
5.14 (1.6–15.7)
5.21 (1.4–18.2)
Levine, 2006 ≥1 Ishak stage
increase
27 Mean 5 (NR; NR) Baseline Ishak
Baseline ALT (elevated)
NR
Mummadi,
2010
≥1 stage
increase on
0–4 scale
53 Median 4 (NR; 2–9) DAPRI
DFIB-4
NR
Perumalswami,
2006
≥1 Ishak stage
increase
40 Mean 3.6 (NR; 0.5–17) Age (older)
Baseline ALT (elevated)
Baseline Ishak (low)
Baseline HAI (higher severity)
NR
Ryder, 2004 ≥1 Ishak stage
increase
33 Median 2.5 (NR; 1.9–9.4) Age (older)
Baseline Ishak (+ﬁbrosis)
1.08* (1.03–1.11)
1.93* (1.3–9.0)
Tamaki, 2013 Not deﬁned 23 Mean 4.9 (2.9; NR) DFIB-4 index/year 3.7 (1.07–12.5)
ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; ETOH, alcohol; GGT, gamma-glutamyl
transpeptidase; HAI, histological activity index; HCV, hepatitis C virus; NR, not reported; RNA, ribonucleic acid.
* Represents adjusted relative risk (RR) instead of OR.
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Table 3 | Outcomes and predictors evaluated and summary of results: clinical outcomes
Study Outcomes evaluated
% with
outcome
Years follow-up
(s.d.; range)
Predictors signiﬁcant
on multivariate analysis HR (95% CI)
Cohorts with patients with a broader range of ﬁbrosis
Ghany, 2011 1. Decompensation:
(i) ascites; (ii) variceal
bleeding; (iii) HE or;
(iv) SBP
2. Hepatic mortality/liver
transplant
1. 13
2. 17
Median 6.3
(NR; 1.4–8.7)
1. Decompensation
Baseline platelets ≤150
Baseline bilirubin ≤0.8 mg/dL
Baseline AST/ALT ≤0.8
>15% decrease in platelets
>15% increase in bilirubin
>15% decrease in albumin
2. Hepatic mortality/transplant
Baseline platelets ≤150
Baseline albumin ≤3.9
>15% increase in albumin
5–15% increase in AST/ALT
2.76 ( 1.47–5.19)
0.37 (0.18–0.75)
0.50 (0.27–0.92)
2.29 (1.26–4.14)
2.62 (1.37–5.00)
3.85 (1.81–8.18)
4.14 (2.29–7.47)
2.32 (1.33–4.06)
3.56 (1.82–6.97)
2.14 (1.16–3.96)
Giannini, 2003 1 year overall mortality 25 ≥1
(NR; NR)
Baseline AST/ALT >1.16
Baseline MELD >9
Baseline CTP score >7
NR
VanDerMeer,
2012
Overall mortality 25 Median 8.1
(NR; NR)
Age (per year)
Gender (male)
Baseline Platelets per 10 9 109/L
Log Baseline AST/ALT (per 0.1)
1.06 (1.03–1.09)
1.90 (1.10–3.29)
0.90 (0.86–0.95)
1.29 (1.11–1.50)
Vergniol, 2011 Overall 5 year mortality 8 Median 3.9
(NR; NR)
Age (older)
Treatment
Liver stiffness
FibroTest
ActiTest
1.03 (1.01–1.04)
0.28 (0.19–0.42)
2.9 (2.0–4.3)
60 (14–255)
0.19 (0.07–0.53)
Cohorts restricted to patients with cirrhosis
Bruno, 2009 1. Decompensation:
(i) ascites; (ii) variceal
bleeding or; (iii) HE
2. Hepatic mortality
3. Overall mortality
1. 40
2. 33
3. 47
Median 14.4
(NR; 0.9–19.5)
1. Decompensation
HCV genotype (1b vs. 2a/c)
Oesophageal varices
Baseline platelets <80
Baseline bilirubin ≥1.2 mL/dL
AFP ≥10 ng/mL
HCC development
2. Hepatic mortality
Age (10 year increase)
Gender (male)
HCV genotype(1b vs. 2a/c)
Oesophageal varices
Creatinine (≥1.2 mg/dl)
MELD >10
Decompensation
HCC development
3. Overall mortality
Age (10 year increase)
Gender (male)
HCV genotype(1b vs. 2a/c)
Oesophageal varices
MELD >10
AFP ≥1 ng/mL
2.17 (1.31–3.59)
2.09 (1.33–3.30)
1.95 (1.08–3.51)
1.79 (1.16–2.76)
1.59 (1.09–2.32)
5.52 (3.77–8.09)
1.61 (1.21–2.13)
1.87 (1.23–2.84)
2.37 (1.33–4.22)
2.27 (1.41–3.66)
3.07 (1.65–5.73)
2.43 (1.57–3.76)
16.9 (9.97-28.6)
8.62 (5.57–13.3)
1.63 (1.28–2.06)
1.88 (1.33–2.66)
1.83 (1.18–2.86)
2.19 (1.47–3.27)
2.15 (1.50–3.09)
1.62 (1.15–2.29)
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evaluated are listed in Figure 2B. The most common clini-
cal characteristics assessed were age, gender and BMI; the
most common laboratory values evaluated were platelet
count and ALT level.
Multivariable analysis was performed in all but two
studies.19, 31 The variables found to be independently
predictive of clinical progression are listed in Tables 3
and 4. Among the variables assessed, baseline platelet
count was the most consistent independent predictor of
clinical outcomes (signiﬁcant on multivariate analysis in
six of 13 studies) followed by age, baseline AST/ALT
ratio, albumin and bilirubin (each signiﬁcant in four
studies).15, 24, 26, 36, 37, 39 Figure 2B depicts the number
of studies in which individual variables were signiﬁcantly
or not signiﬁcantly predictive of clinical outcomes in
multivariate analyses.
Mathematical prediction models
Five studies provided prediction models, three for ﬁbro-
sis progression and four for clinical outcomes (Table
S6).23, 26, 32, 39, 40 Four of the models were derived from
the HALT-C study. All the prediction models are pri-
marily comprised of baseline laboratory results. Only
one of the models incorporated longitudinal data. None
of the models had been validated in external CHC
cohorts and only two models reported the associated
area under the receiver operating characteristic
curve.23, 40
Quality assessment and risk of bias
Studies evaluating predictors of histological progres-
sion were of varying quality, whereas studies investi-
gating predictors of clinical outcomes or studies
investigating combined outcomes were all of high
quality except for one study.31 Six studies on histologi-
cal progression included a small number of patients
with advanced ﬁbrosis or cirrhosis on initial biopsy
who were not able to progress according to the
author’s deﬁnition.17, 18, 25, 28, 33, 38 Two studies eval-
uated select cohorts (Levine et al. evaluated untreated
Irish women who acquired HCV infection during
pregnancy only, and Livingston et al. evaluated only
treatment na€ıve Alaska Native and American Indian
persons) and were scored as having limited representa-
tiveness.30, 31 The remaining studies were scored as
being at least somewhat representative of the average
patient with CHC in the community (Table S2).
DISCUSSION
Although there is abundant literature on the topic of
predictors of histological and clinical outcomes for
patients with CHC, only 29 studies met our inclusion
criteria which captured studies with a longitudinal study
design in broad patient populations. Within the 29 stud-
ies included, the incidence of outcomes varied widely:
16–61% during a median follow-up of 2.5–10 years for
ﬁbrosis progression; 13–40% over 2.3–14.4 years for
Table 3 | (Continued)
Study Outcomes evaluated
% with
outcome
Years follow-up
(s.d.; range)
Predictors signiﬁcant
on multivariate analysis HR (95% CI)
Decompensation
HCC development
7.08 (4.88–10.2)
3.80 (2.67–5.42)
Rincon, 2013 Decompensation:
(i) ascites; (ii) variceal
bleeding or; (iii) HE
29 Median 2.3
(NR; 0.2–9.2)
HVPG
Baseline albumin
1.11 (1.05–1.17)
0.42 (0.22–0.82)
Sinn, 2008 First occurrence of:
(i) ≥2 increase CTP
score; (ii) HCC;
(iii) SBP; (iv) variceal
bleed; (v) HE or;
(vi) hepatic mortality
22 Median 4.6
(NR; 1–12.6)
Age > 55
Gender (Male)
Diabetes
Baseline platelets <140
Baseline APRI >1
2.2 (1.4–3.6)
1.7 (1.2–2.3)
1.8 (1.3–2.7)
4.9 (3.4–7.2)
5.4 (3.5–8.3)
Sinn, 2013 Disease progression
using same 2008
deﬁnition
14 Median 4.5
(NR; 1–12.6)
Baseline ALT >26 (male)
Baseline ALT> 23 (female)
Baseline platelets (low, male)
Baseline platelets (low, female)
5.35 (1.05–27.3)
4.40 (1.12–15.8)
0.98 (0.96–0.99)
0.97 (0.96–0.98)
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; APRI, aspartate aminotransferase to platelet ratio index; AST, aspartate
aminotransferase; CTP, Child–Turcotte–Pugh; CI, conﬁdence interval; HE, hepatic encephalopathy; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus; HVPG, hepatic vein pressure gradient; HR, hazard ratio; MELD, model for end-stage liver disease; NR, not
reported; SBP, spontaneous bacterial peritonitis
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hepatic decompensation; and 8–47% over 3.9–14.4 years
follow-up for overall mortality. The wide range in inci-
dence of outcomes highlights the heterogeneity in patient
population evaluated, stage of liver disease at enrollment,
duration of follow-up, and deﬁnition of outcomes.
Interestingly, higher rates of outcomes did not clearly
Table 4 | Outcomes and predictors evaluated and summary of results: histological progression and clinical outcomes
Study Outcomes evaluated % with Outcome
Years Follow-up
(s.d.; range)
Predictors signiﬁcant
on multivariate
analysis HR (95% CI)
Dienstag,
2011
1. Progression to cirrhosis
2. Any clinical outcome:
(i) hepatic decompensation:
ascites/variceal bleeding/HE/
SBP; (ii) transplant; (iii) HCC;
(iv) ≥7 CTP score; (v) hepatic
mortality; (vi) overall mortality
1. 29
2. 31
Median 6
(NR; 0.8–7)
Not performed
Everhart,
2009
Combined outcome: ≥2
Increase in Ishak, hepatic
mortality or hepatic
decompensation (≥7 CTP
score, ascites, variceal
bleed, HE)
28 Mean 3.5
(NR; NR)
Baseline Ishak
(cirrhosis)
HOMA2-IR
(quartiles)
Baseline steatosis
(if cirrhosis)
Mallory bodies
1.92 (1.12–3.28)
1.25 (1.08–1.45)
0.49 (0.35–0.70)
1.59 (1.10–2.31)
Fontana,
2010
1. ≥2 Increase in Ishak
2. Clinical outcomes:
(i) Hepatic decompensation:
ascites/variceal bleeding/HE/
SBP; (ii) HCC; (iii) ≥7 CTP
score or; (iv) overall mortality
1. 34
2. 15
Mean 4.25
(NR; NR)
1. Histological progression
Baseline platelet
(per 50 K, low)
Baseline log HA
2. Any clinical
outcome
Baseline bilirubin
(elevated)
Baseline INR (>1.0)
Baseline albumin (low)
Baseline logYKL-40
0.72 (0.57–0.91)
2.42 (0.27–4.47)
2.42 (1.42–4.13)
2.25 (1.30–3.89)
0.20 (0.10–0.38)
2.44 (1.28–4.63)
Ghany,
2010
1. ≥2 Increase in Ishak
2. Clinical outcomes:
(i) Hepatic decompensation:
ascites/variceal bleeding/HE/
SBP; (ii) ≥7 CTP score or;
(iii) hepatic mortality
1. 28
2. 13
Mean 3.5
(NR; NR)
1. Histological progression
Baseline BMI (high)
Baseline platelets (low)
Baseline steatosis
2. Any clinical outcome
Baseline Log
AST/ALT (high)
Baseline bilirubin
(elevated)
Baseline albumin
(low)
Baseline platelets/
50 K (low)
NR
3.34 (1.84–6.06)
1.82 (1.37–2.42)
0.20 (0.13–0.32)
0.59 (0.49–0.72)
Livingston,
2010
1. ≥1 increase in Ishak
2. Hepatic decompensation:
ascites/oesophageal
varices/HE/coagulopathy
1. 60
2. 17
Mean 6.2
(NR; 2.3–13.3)
Not performed
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CTP, Child-Turcotte-Pugh; CI, conﬁdence
interval; HA, hyaluronic acid; HE, hepatic encephalopathy; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HR, hazard
ratio; INR, international normalised ratio; NR, not reported; RNA, ribonucleic acid; SBP, spontaneous bacterial peritonitis.
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correlate with longer durations of follow-up or more
advanced disease at baseline across studies, pointing to
more complex underlying interactions driving outcomes.
Although the incidence data were not conducive to pro-
viding consensus outcome rates, we were able to identify
risk factors that have most consistently been associated
with outcomes of interest. Baseline steatosis and ﬁbrosis
score were the most consistent predictors of ﬁbrosis pro-
gression and baseline platelet count, AST/ALT ratio,
albumin, bilirubin and patient age were the most consis-
tent predictors of clinical outcomes.
The variables identiﬁed as being most predictive of
outcomes were not unexpectedly markers of more
advanced liver disease. Though the overall ﬁnding that
patients with more advanced disease are at higher risk
for adverse outcomes is not novel, our study is the ﬁrst
to systematically identify the speciﬁc risk factors from
among the many markers of advanced liver disease that
portends worse prognosis. For example, among the labo-
ratory markers of more advanced liver disease, platelet
count, bilirubin, albumin and AST/ALT ratio conveyed
meaningful risk information whereas INR, AST, ALT
and MELD score did not. Differences in study design
made it difﬁcult to identify clear cut-off values for each
predictor apart from platelet count with values ≤150 000/
uL consistently associated with worse prognosis. Further-
more, individual laboratory markers may be less reliable
in predicting outcomes than panels of markers such as
aspartate aminotransferase to platelet ratio index (APRI),
FIB-4, Fibrotest and/or measurements of liver stiffness.
The ﬁnding that patients with more advanced disease
have greater risk of disease progression suggests there
may be subsets of patients who are rapid progressors.
Understanding whether some patients are destined to be
rapid progressors and being able to identify these patients
at an early stage will help target limited resources to treat
those patients who will derive the most beneﬁt. Though
none of the existing predictive models have been exter-
nally validated, the model developed by Ghany and col-
leagues is most readily applicable in clinical practice as it
is based on routinely available data and evaluates impor-
tant liver-related clinical outcomes.26
Examining the results in more detail yielded several
useful insights. First, the ﬁnding of steatosis as a predictor
of outcomes highlights a potential modiﬁable risk factor
associated with disease progression. This is particularly
relevant given the evolving obesity epidemic. Our data
suggest that patients may beneﬁt from aggressive lifestyle
interventions in addition to other standard of care treat-
ment for patients with CHC. The prognostic information
gained from baseline liver biopsy results suggests that
liver biopsies not only provide information regarding cur-
rent staging of liver disease but also useful prognostic
information. As performance of liver biopsies continue to
decline, evaluating whether noninvasive assessment of
ﬁbrosis and steatosis will provide the same prognostic
information would be important. Though only one study
included in our review used an additional modality to
assess liver ﬁbrosis in conjunction with biopsy, this study
showed that liver stiffness measurements were associated
with overall mortality.40
Our review also highlights several areas for improve-
ment for future studies on predictors of disease progres-
sion in CHC. Analysis of the individual predictive value
of each risk factor found that there was a notable lack of
incorporation of longitudinal variables. In the few studies
that did assess longitudinal data, these variables were
usually restricted to laboratory values, predominantly
AST and ALT levels. These models do not mirror clinical
practice where assessments of risk of disease progression
are based on the pattern of a patient’s test results over
time. Models restricted to only baseline data also cannot
distinguish between patients with similar initial data but
who go on to have distinct disease courses and outcomes.
Future studies can also beneﬁt from implementing stan-
dardised deﬁnitions and criteria for outcomes and
employing a panel of investigators to adjudicate out-
comes as the variability in deﬁnition of predictor and
outcome variables was one of the biggest challenges.
There are other limitations to our review such as sam-
ple selection bias, sampling error and misclassiﬁcation
bias in studies requiring paired biopsies. In the majority
of studies, biopsies were assessed by a single pathologist
and criteria for adequacy of biopsies was described in
only 14 of 21 studies. Finally, the variability in duration
of follow-up impacts not only incidence rates of out-
comes but also predictiveness of variables examined.
In summary, this systematic review demonstrated that
while there is an abundance of literature on factors asso-
ciated with histological and/or clinical progression in
CHC, there is a lack of longitudinal studies of representa-
tive, untreated, well characterised patients followed for a
sufﬁciently long duration to allow the development of
simple prediction models. Despite the limitations inher-
ent to the existing literature, we were able to identify spe-
ciﬁc risk factors that have been consistently identiﬁed as
being independently predictive of disease progression. By
selecting studies consisting of broad patient populations
and those that evaluated routinely obtained clinical data,
our ﬁndings can be generalised to and applied in many
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clinical settings. From a policy standpoint, we have high-
lighted that it is possible to identify patients at higher risk
for adverse outcomes. Policies that target costly new
HCV therapies to these patients who would derive the
most beneﬁt will maximise their cost effectiveness. The
availability of risk prediction tools that can be applied in
the clinic will help both physicians and patients decide
whether to embark on HCV treatment now or to wait for
more affordable treatment. These types of tools will be
particularly important in resource-limited countries and
must therefore be validated in broad patient populations.
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